Ordinary Shares, nominal value EUR0.10 per share

DBV Technologies S.A.

107 Avenue de la Republique, Chatillon, I0, 92320

Information concerning the executive officers and directors of Bpifrance Participations, Bpifrance Investissement, CDC, EPIC and Bpifrance required to be disclosed in response to Item 2 and General Instruction C to Schedule 13D is provided in Exhibit 99.2 to this Amendment and incorporated herein by reference.

None of the Reporting Persons, nor, to the best of their knowledge, any of the persons referred to in Exhibit 99.2 has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws.

Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: Items 7 through 11 and 13 of each of the cover pages of this Amendment are incorporated herein by reference. As of January 7, 2026, (i) Bpifrance Participations holds directly 10,672,462 Ordinary Shares, which represent 4.6% of the Issuer's outstanding Ordinary Shares, and (ii) Innobio holds directly 226,133 Ordinary Shares, which represents 0.1% of the Issuer's outstanding Ordinary Shares. As of January 7, 2026, neither Bpifrance, Bpifrance Investissement, EPIC nor CDC holds any Ordinary Shares directly. Bpifrance Investissement may be deemed to be the beneficial owner of the 226,133 Ordinary Shares held by Innobio, through its management of Innobio. Bpifrance may be deemed to be the beneficial owner of 10,898,595 Ordinary Shares, which represent 4.7% of the Issuer's outstanding Ordinary Shares, indirectly through its sole ownership of Bpifrance Participations, which is the parent company of Bpifrance Investissement. EPIC and CDC may be deemed to be the beneficial owners of 10,898,595 Ordinary Shares, indirectly through their joint ownership and control of Bpifrance. The percentage of Ordinary Shares beneficially owned by each Reporting Person is based on 232,047,938 Ordinary Shares of the Issuer that are outstanding (based on particular information published by the Issuer) as of December 31, 2025. The amount of outstanding Ordinary Shares disclosed in the prior sentence is calculated under U.S. law, which requires treasury shares to be excluded from the calculation of outstanding shares. Under French law, treasury shares are required to be included in the calculation of outstanding shares.

Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: Items 7 through 11 and 13 of each of the cover pages of this Amendment are incorporated herein by reference.

Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: The information set forth in Item 4 is hereby incorporated by reference into this Item 5(c). Except as disclosed in this Amendment, there have been no reportable transactions with respect to the Ordinary Shares of the Issuer since the filing of Amendment No. 9 to this Schedule 13D, or, to the best of their knowledge, any of the persons referred to in Exhibit 99.2.

As of January 7, 2026, pursuant to the exercise of warrants of the Issuer exercised by various holders and Bpifrance Participations' recent sales of Ordinary Shares in the open market, Bpifrance Participations has ceased to be the beneficial owner of more than five percent (5%) of the outstanding Ordinary Shares. Accordingly, the filing of this Amendment 10 represents the final amendment to Schedule 13D for the Reporting Persons and constitutes an exit filing for the Reporting Persons.